Rebif for Multiple Sclerosis
Rebif, an Interferon Drug, is a Great Choice for Fighting Your MS
Rebif is a naturally-occuring interferon that is used to combat forms of multiple sclerosis. It is believed to be one of the most effective medications on the market.
What is Rebif?
Rebif, a multiple sclerosis disease-modifying drug, consists of amino acids that are naturally found in the human body. The drug itself is referred to as an "interferon", something found within the central nervous system. Rebif is a naturally-occuring "beta" interferon which duplicates this chemical's function in the body. It appears to decrease the amount and severity of autoimmune attacks on the myelin-covered nerves. Consequently, less nerve damage may occur, less scar lesions may develop in the brain and/or spinal cord, and less disability may result.
Rebif: Administration
Rebif is an injectable drug: it is delivered by needle subcutaneously (under the skin.) This medication is taken 3X a week, and 44 mcg is delivered with each injection. Many scientists and neurologists believe that higher doses of interferon several times a week (including both Rebif and Betaseron) are the best defense against multiple sclerosis relapses. Rebif can be self-administered with an autoinjector.
Rebif: Advantages and Side-Effects
Rebif is advantageous because it is administered only 3X a week (only Avonex is taken less, but it is a weaker formula.) Rebif is also pre-mixed for easy use. Many believe that higher-dose interferons are more effective than other disease-modifying drugs. Side-effects from Rebif can include flu-like symptoms (fever, muscle aches, headache, etc.), elevated liver tests, and possible depression. Patients need to weigh the pros and cons, decide which drug qualities they are looking for, and determine if Rebif is their medication of choice.
*****For more information about MS, check out the Multiple Sclerosis Suite.
For related neurological information, visit the Neurological ARTICLE INDEX and Blog.
*********************************************************************************************************
